ArQule, Inc.
http://www.arqule.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ArQule, Inc.
Basilea Looks To Progress Cancer Pipeline As It Expands Zevtera Use
Switzerland’s Basilea Pharmaceutica is progressing its lead oncology candidates and a second late-stage US clinical trial of ceftobiprole in difficult-to-treat infections.
Deal Watch: BMS Looks To Molecular Templates’ Engineered Toxin Bodies In Cancer
Plus recent deals involving AbbVie/Caribou, Sanofi/i2O, Merck & Co./Starpharma, Protalix/SarcoMed, Targovax/Papyrus, Medivir/Ubiquigent, Eton/Azurity
Loxo Lays Out Plans For BTK Inhibitor LOXO-305 In CLL
The company said investigators had been choosing the drug over Venclexta due to its less cumbersome administration, especially amid the COVID-19 pandemic.
LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Cyclis Pharmaceuticals, Inc.